Form 4 for FBIO Fortress Biotech, Inc.
Accepted 2023-12-22 00:00:00 ET · period of report 2023-12-20 · accession 0001104659-23-128788 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-20 | FBIO | Jin David | CFO | A - Grant | $0.00 | +140.0K | 235.9K | +146% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK, PAR VALUE $0.001 | 2023-12-20 | A | A | 140,000 | $0.00 | 235,916 | D | — | — | (F2) Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. (F1) Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. (F3) Total holdings include 230,000 shares underlying deferred restricted stock units. |